Linear mixed‐effects model of QTc prolongation for olmesartan medoxomil-Reference-Cited by-同舟云学术

Linear mixed‐effects model of QTc prolongation for olmesartan medoxomil

Published:2015-08-24 Issue:1 Volume:56 Page:96-100
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Song SaeHeum¹,Matsushima Nobuko²,Lee James¹,Mendell Jeanne¹

Affiliation:

1. Daiichi Sankyo Pharma DevelopmentEdisonNJUSA

2. Daiichi Sankyo Co, LtdTokyoJapan

Funder

Daiichi Sankyo Pharma Development

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.572

Reference13 articles.

1. Benicar (olmesartan medoxomil) tablets product label by Daiichi Sankyo Inc. (revised 02/ 2010).http://www.accessdata.fda.gov/Scripts/cder/Drugsat FDA

2. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

3. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study

4. US Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non‐antiarrhythmic drugs.2005.http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073153.pdf. Accessed April 28 2015.

5. A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods;Journal of Pharmacokinetics and Pharmacodynamics;2018-03-19

2. Population pharmacokinetics of moxifloxacin and its concentration–QT interval relationship modeling in Chinese healthy volunteers;Acta Pharmacologica Sinica;2017-07-17

3. Estimation of QT interval prolongation through model-averaging;Journal of Pharmacokinetics and Pharmacodynamics;2017-04-18

4. Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension;European Journal of Drug Metabolism and Pharmacokinetics;2016-08-17